Lumasiran in Hyperoxalaemic Patients on Haemodialysis (LHOxH)

This study will look at how well a drug that reduced the amount of oxalate in the body works in patients that have kidney disease and need dialysis treatment. People with kidney disease often have higher levels of oxalate in the blood. People with kidney disease are also at higher risk of having heart attacks, heart disease and strokes (these are called cardiovascular diseases). It is thought that high oxalate levels may increase the risk of these diseases. This study will investigate if this medicine can lower the amount of oxalate in the blood of dialysis patients and see if there is any change in the health of their heart. This medicine is already used for people who have high oxalate levels because of a genetic cause and has been used safely for patients on dialysis.

The study will put the participants randomly into either the group getting the study medicine or the group getting a placebo (this will be a solution of saline water). Neither participants not the doctors will know whether the drug or placebo is given until after the end of the study.

At the start of the study all the participants will have an echocardiogram (an ultrasound of the heart) and again 6 months later at the end of the study. We will also take blood tests once a month when the participants come for dialysis.

Study Overview

• Status: Recruiting
• Conditions: Cardiovascular Disease; Cardiovascular Risk Factor; Haemodialysis; Chronic Kidney Disease Requiring Chronic Dialysis; Hyperoxalemia
• Intervention / Treatment: Drug: Lumasiran; Drug: 0.9% Sodium Chloride (placebo)

Detailed Description

This is an investigator-initiated, double-blind, phase II two-centre medications study with an intervention and placebo arm.

The principal objective of this study is to establish if the administration of lumasiran versus placebo can effectively lower pre-dialysis oxalate levels in hyperoxalaemic haemodialysis patients with any cause of ESKD (end stage kidney disease) except known primary hyperoxaluria.

The hypothesis is that compared to placebo, the administration of lumasiran (the study drug) will reduce serum oxalate levels at 3-6 months post first dose in hyperoxalaemic haemodialysis patients.

This study will evaluate the use of lumasiran in haemodialysis patients. Lumasiran will be dosed as per the SmPC published by the European Medicines Agency. Monthly pre-dialysis plasma oxalate measurements will be taken to assess the effect of lumasiran on lowering the oxalate levels versus a placebo. Thus far studies have shown lumasiran to be well tolerated. The tolerability in this patient cohort will be evaluated and monitor inflammatory and cardiovascular biomarkers in addition to cardiac imaging with echocardiograms.

• Study Type: Interventional
• Enrollment (Estimated): 50
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Gerlineke MC Hawkins-van der Cingel, MBBS; Phone Number: + 49 030 450 530067; Email: gerlineke.hawkins-van-der-cingel@charite.de
• Study Contact Backup: Name: Felix Knauf, MD; Phone Number: + 49 030 450 530066; Email: felix.knauf@charite.de

Study Locations

• Germany
  • Berlin, Germany
    • Recruiting
    • Charite Universtiätsmedizin
    • Contact: Gerlineke Hawkins-van der Cingel, MBBS

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Male or female patients
• Aged between 18 and 80 years old at the start of the study.
• Women of child-bearing potential to consent to either abstinence or the use of contraception during the study period
• Patients must have capacity to give written, informed consent to participate in the study prior to commencing the study. They must be fully aware of the aims, nature, planned interventions and potential risks of participating in the study. This consent must be obtained by the time of participant inclusion.
• Established and stable on haemodialysis for at least 2 months
• Thrice weekly haemodialysis
• In possession of permanent dialysis access - either arterio-venous fistula (AVF) or graft (AVG) or permanent dialysis catheter/tunnelled haemodialysis line (THL).
• ESKD not caused by previously diagnosed primary hyperoxaluria.
• Mean baseline serum oxalate level of ≥20 μmol/L
• No recent (within last 2 months) significant changes to regular medications or diet

Exclusion Criteria:

• Known diagnosis of PH1, 2 or 3; or a pathological mutation documented to cause primary hyperoxaluria.
• Established on haemodialysis for less than 2 months.
• On peritoneal dialysis.
• Combined haemodialysis and peritoneal dialysis.
• Temporary or poorly functioning haemodialysis access
• Pregnancy, planning pregnancy or currently breast feeding.
• Co-morbidity of an enteric disorder such as Inflammatory Bowel Disease (IBD), short gut syndrome, or a malabsorptive disorder.
• Decompensated Liver failure.
• Intercurrent active infection and/or antibiotic treatment.
• Currently on Vitamin C treatment with a daily dose of more than 250mg.
• Terminal illness and/or life expectancy of less than 1 year.
• Currently relapsed or uncontrolled and symptomatic psychiatric disorder preventing compliance with the study.
• Participants institutionalised by court or government order.
• Patients who could be coerced due to dependency on the sponsor, the investigator, the trial sites or test centres.
• Deranged liver function tests: If alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is more than twice the upper limit

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo; Placebo injection with 0.9% sodium chloride	Drug: 0.9% Sodium Chloride (placebo); Placebo, subcutaneous injection, given as three monthly loading doses followed by one further maintenance dose.
Experimental: Lumasiran, treatment arm; Treatment arm with Lumasiran	Drug: Lumasiran; Subcutaneous injection, given as three monthly loading doses followed by one further maintenance dose.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pre-dialysis Plasma Oxalate concentration	The primary endpoint is the percentage change in pre-dialysis plasma oxalate levels in non-primary hyperoxaluria patients with raised plasma oxalate levels who are receiving maintenance haemodialysis.	It will be measured at baseline and month 1-6 (weeks 4, 8, 12, 16, 20 and 24).

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Absolute change in pre-dialysis mean plasma	Absolute change in pre-dialysis mean plasma oxalate levels from baseline to month 3-6, comparing the treatment group with the placebo group.	Baseline to month 3-6,
Side effects (tolerability)	Tolerability will be assessed using an adapted FACIT Instrument validated questionnaire (severity of side effects rated on scale between 0 and 4). Again, the answers of the two study arms will be compared.	Monthly - month 0-6

Collaborators and Investigators

• Sponsor: Charite University, Berlin, Germany
• Collaborators: Alnylam Pharmaceuticals
• Investigators: Principal Investigator: Felix Knauf, MD, Charite Universitatsmedizin

Study record dates

Study Major Dates

• Study Start (Actual): April 14, 2024
• Primary Completion (Estimated): January 30, 2025
• Study Completion (Estimated): March 1, 2025

Study Registration Dates

• First Submitted: January 17, 2024
• First Submitted That Met QC Criteria: January 17, 2024
• First Posted (Actual): January 26, 2024

Study Record Updates

• Last Update Posted (Actual): August 21, 2024
• Last Update Submitted That Met QC Criteria: August 19, 2024
• Last Verified: August 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Urologic Diseases; Disease Attributes; Renal Insufficiency; Chronic Disease; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Cardiovascular Diseases; Kidney Diseases; Renal Insufficiency, Chronic; Renal Agents; Lumasiran
• Other Study ID Numbers: 20018510; 2022-002681-32 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No